新诊断与复发性巨细胞动脉炎:GiACTA 试验基线数据
该研究描述了纳入托珠单抗随机试验的 251 例巨细胞动脉炎(GCA)患者的入组标准和临床特征,其中新诊断 119 例(47%),复发 132 例(53%)。结果显示复发患者体重和 BMI 更高,基线抑郁和骨量减少/骨质疏松患病率更高,且超过三分之一患者基于大血管影像学入组。
要点
- 复发患者较新诊断患者体重和 BMI 更高,抑郁和骨量减少/骨质疏松更常见。
- 62% 颞动脉活检阳性,37% 基于横断面影像学入组。
核心结论
- GiACTA 人群人口学特征反映 GCA 流行病学特点,复发患者中与糖皮质激素相关的基线合并症更普遍,提示需要新的 GCA 治疗选择。
研究设计与样本
- 报告纳入托珠单抗随机试验的 251 例活动性 GCA 患者的入组标准和临床特征,新诊断定义为基线前 ≤6 周诊断,复发定义为基线前 >6 周诊断且连续 ≥2 周泼尼松 ≥40mg/天。
主要发现
- 251 例患者中新诊断 119 例(47%),复发 132 例(53%),两亚组平均年龄均为 69 岁,75% 为女性。
- 复发患者体重更高:女性平均差异 4.18kg(95%CI 0.49-7.87,P=0.027),男性 8.25kg(95%CI 1.42-15.09,P=0.019);BMI 更高:女性差异 1.72kg/m2(95%CI 0.44-2.99,P=0.009),男性 2.85kg/m2(95%CI 0.32-5.37,P=0.028)。
- 复发患者基线抑郁患病率 16% 对比新诊断 4%(P=0.002),骨量减少/骨质疏松 33% 对比 23%(P=0.062)。
- 诊断时 67% 有新发头痛,34% 有口腔疼痛/下颌跛行,五分之一有风湿性多肌痛症状但无颅部表现,62% 颞动脉活检阳性,37% 基于横断面影像学入组。
关键数值与推荐
- 新诊断 GCA 定义为基线前 ≤6 周诊断;复发 GCA 定义为基线前 >6 周诊断且连续 ≥2 周泼尼松 ≥40mg/天;所有患者基线前 6 周内均有活动性 GCA。
临床怎么用
- 复发 GCA 患者更常携带糖皮质激素相关合并症(如抑郁、骨量减少/骨质疏松),临床应关注这些共病并考虑减少激素暴露的治疗策略。
- 超过三分之一患者基于大血管影像学入组,提示影像学在 GCA 诊断和入组中的重要作用。
局限性
- 所有统计结果均为探索性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To report entry criteria and clinical features of patients with newly diagnosed and relapsing giant cell arteritis (GCA) enrolled in a randomized trial of tocilizumab, an interleukin-6 receptor-alpha inhibitor. METHODS: Newly diagnosed GCA was defined as diagnosis ≤6 weeks before baseline. Relapsing GCA was defined as diagnosis >6 weeks before baseline with ≥2 consecutive weeks of prednisone ≥40mg/day. All patients had active GCA within 6 weeks of baseline. All statistical results are exploratory. RESULTS: Of 251 patients, 119 (47%) had newly diagnosed and 132 (53%) had relapsing GCA. Mean age was 69 years in both subsets; 75% were women. Relapsing patients were heavier [difference in means (95% CI): women, 4.18kg (0.49-7.87, P = 0.027); men, 8.25kg (1.42-15.09, P = 0.019)] and had higher mean body mass index [difference in means (95% CI): women, 1.72kg/m2 (0.44-2.99, P = 0.009); men, 2.85kg/m2 (0.32-5.37, P = 0.028)]. Relapsers had higher baseline prevalence of depression (16% vs. 4%) and osteopenia/osteoporosis (33% vs. 23%, P = 0.002 and P = 0.062, respectively). At diagnosis, 67% had new-onset headaches; 34% had mouth pain/jaw claudication. One-fifth had polymyalgia rheumatica symptoms but no cranial manifestations; 62% had positive temporal artery biopsy findings; 37% were enrolled on the basis of cross-sectional imaging study findings. CONCLUSIONS: Demographics of the GiACTA population reflect the epidemiologic profile of GCA. Baseline comorbidities associated with glucocorticoids were more prevalent among relapsing patients than among those with newly diagnosed disease, highlighting the need for new GCA treatment options. More than one-third of patients were enrolled based on large-vessel imaging.
引用
- Tuckwell K, Collinson N, Dimonaco S, et al. Newly diagnosed vs. relapsing giant cell arteritis: Baseline data from the GiACTA trial. Semin Arthritis Rheum. 2016. PMID: 27998620. doi:10.1016/j.semarthrit.2016.11.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。